Atrium Innovations acquires the assets of Trophic Canada for total cash consideration of $11M

NewsGuard 100/100 Score

Acquisition provides Atrium with a complementary platform in the Canadian Market

Atrium Innovations Inc. (TSX: ATB), a recognized leading developer, manufacturer and marketer of professionally endorsed, science-based products for the health and nutrition industry, today announced the purchase of the assets of Trophic Canada, a leading manufacturer and distributor of vitamins, minerals and herbal supplements in the Canadian Health Food Store (HFS) market.

Trophic's two brands, Trophic and Wild Rose, comprising 150 products, are sold in over 900 specialized health food stores. The Company was founded in 1967 and is well known for its superior quality ingredients, formulations, rigorous testing and good manufacturing practices. Over the years, Trophic's brands have gained a solid reputation within the Health Food Store channel in the Canadian natural health industry. The annualized revenues of Trophic are approximately US$7.5 million.

"The acquisition of Trophic will provide Atrium with a stronger and complementary foothold and greater visibility in the Canadian market," said Pierre Fitzgibbon, Atrium's President and CEO. "Trophic's respected brands are supported by a well established access to the Health Food Store channel. The two brands' high quality products, approach to science and market positioning are a perfect fit with Atrium's DNA. We see considerable potential to grow Trophic and leverage its distribution strength by adding complementary products and by gaining direct access to the specialty retailers in the Canadian market. As we are a relatively small player in the Canadian market, this transaction clearly signals our accelerating emphasis on growing Atrium in its multi-channel strategy and our aim of assuming a major role in our domestic market."

Under the terms of the transaction, Atrium acquired the assets of Trophic for a total cash consideration of approximately US$11 million without any forward purchase price adjustments. The acquisition is immediately accretive to earnings without factoring future revenues and operating synergies. The transaction was completed with an effective date of March 17, 2010.

Source:

ATRIUM INNOVATIONS INC.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Renaissance of "food as medicine" in modern clinical trials